Back to the main list of congress faculty

BIOGRAPHY   Howard Feldman, MD Professor and Head, Division of Neurology University of British Columbia Director, UBC Alzheimer Clinical Trials Program Vancouver, British Columbia Canada Howard Feldman, MD, CM, FRCP(C) is Professor and Head of the Division of Neurology University of British Columbia (UBC) and Vancouver Hospital, Vancouver, Canada. He holds an appointment as well as Adjunct Professor at the McGill Centre for Studies in Aging in Montreal. Dr Feldman is the Director of the Alzheimer Clinical Trials Program at UBC and has been the director of the UBC Head Injury Assessment Program. In his clinical research activities Dr Feldman has been active in both epidemiological and clinical diagnostic/therapeutic studies in Alzheimer’s disease and other degenerative dementias. He has been been principal investigator for several large international Alzheimer’s disease clinical trials and is the principal investigator of the ACCORD study a large multicenter Canadian cohort study of dementia syndromes funded through the Canadian Institutes of Heath Research (CIHR). Dr Feldman’s work has been published in numerous peer reviewed professional journals. He has more than 125 publications and has contributed important publications on biomarkers and treatment of Alzheimer's disease. He has lectured globally on Alzheimer-related issues including the presentation and progression of Alzheimer’s disease as well as emerging treatment strategies. A member of several professional societies, including the American Academy of Neurology, the Canadian Neurological Sciences and the Canadian Consortium of Clinical Cognitive Research Centers (C5R), Dr Feldman has been the president of the C5R. He has been active as a member of the steering committee of the International Harmonization of Dementia Drug Development. He is a member of numerous scientific advisory boards including Alzheimer’s Disease International, and has been advisor to the European Institute of Women’s Health. He serves on the editorial boards of a number of journals and has been a peer reviewer of Alzheimer’s disease grants and articles for granting agencies and journals.